UY37811A - Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma - Google Patents

Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma

Info

Publication number
UY37811A
UY37811A UY0001037811A UY37811A UY37811A UY 37811 A UY37811 A UY 37811A UY 0001037811 A UY0001037811 A UY 0001037811A UY 37811 A UY37811 A UY 37811A UY 37811 A UY37811 A UY 37811A
Authority
UY
Uruguay
Prior art keywords
antigen
immunogenic composition
preparation
same
improved stability
Prior art date
Application number
UY0001037811A
Other languages
English (en)
Inventor
Rakesh Kumar
Jit Sharma Inder
Anil Vyankatrao Shitole
Doddapaneni Manohar
Jyoti Sharma Hitt
Original Assignee
Serum Inst Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Pvt Ltd filed Critical Serum Inst Of India Pvt Ltd
Publication of UY37811A publication Critical patent/UY37811A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición inmunogénica que comprende antígeno del toxoide diftérico (D), antígeno del toxoide tetánico (T), antígeno de superficie de la hepatitis B (HBsAg), antígeno de B. pertussis inactivado de células enteras (wP), sacárido capsular de Haemophilus influenzae tipo B (Hib) conjugado a una proteína transportadora, antígeno del virus de la polio Inactivado (IPV) y adicionalmente uno o más antígenos y el método para prepararlos. Una vacuna combinada completamente líquida, que muestra inmunogenicidad/estabilidad mejorada y reactogenicidad reducida
UY0001037811A 2017-07-18 2018-07-17 Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma UY37811A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721025513 2017-07-18

Publications (1)

Publication Number Publication Date
UY37811A true UY37811A (es) 2019-01-02

Family

ID=63556364

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037811A UY37811A (es) 2017-07-18 2018-07-17 Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma

Country Status (20)

Country Link
US (1) US11179453B2 (es)
EP (1) EP3655024A1 (es)
JP (1) JP7404226B2 (es)
KR (1) KR102657910B1 (es)
CN (1) CN111032078A (es)
AU (1) AU2018302767A1 (es)
BR (1) BR112020000999A2 (es)
CA (1) CA3070039A1 (es)
CO (1) CO2020001765A2 (es)
EA (1) EA202090316A1 (es)
GE (1) GEP20227386B (es)
JO (1) JOP20180069B1 (es)
MX (1) MX2020000441A (es)
PE (1) PE20201443A1 (es)
PH (1) PH12020500133A1 (es)
SG (1) SG11202000224SA (es)
TW (1) TWI786153B (es)
UY (1) UY37811A (es)
WO (1) WO2019016654A1 (es)
ZA (1) ZA202000889B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101408113B1 (ko) * 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
AU2007224734C1 (en) 2006-03-10 2016-07-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Live attenuated Bordetella strains as a single dose vaccine against whooping cough
AU2010243708C1 (en) 2009-04-28 2014-10-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
SG11202003333WA (en) * 2017-10-18 2020-05-28 Pasteur Institut Bordetella strains expressing serotype 3 fimbriae
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂系统及制备该佐剂的方法
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
EP3988290A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method for manufacturing a spectacle lens
EP3988289A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method of manufacturing a spectacle lens
EP3988288A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method of manufacturing a spectacle lens
KR20220076405A (ko) * 2020-11-30 2022-06-08 주식회사 엘지화학 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835663B1 (en) 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising Hepatitis B surface antigen and other antigens
CA2222455C (en) 1995-03-22 2013-05-28 Smithkline Beecham Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
CA2303105A1 (en) 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1004314A1 (fr) 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0616226D0 (en) 2006-08-15 2006-09-27 Novartis Ag Processes
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
CN103442730B (zh) * 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
KR20160040290A (ko) * 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
MA52400B1 (fr) * 2015-09-16 2023-01-31 Lg Chemical Ltd Composition de vaccin combinée pour administration multiple

Also Published As

Publication number Publication date
TWI786153B (zh) 2022-12-11
KR102657910B1 (ko) 2024-04-18
US11179453B2 (en) 2021-11-23
WO2019016654A1 (en) 2019-01-24
MX2020000441A (es) 2020-08-17
JP2020527571A (ja) 2020-09-10
JOP20180069B1 (ar) 2022-09-15
BR112020000999A2 (pt) 2020-07-14
CO2020001765A2 (es) 2020-05-29
JOP20180069A1 (ar) 2019-01-18
SG11202000224SA (en) 2020-02-27
JP7404226B2 (ja) 2023-12-25
EA202090316A1 (ru) 2020-12-08
ZA202000889B (en) 2021-06-30
EP3655024A1 (en) 2020-05-27
TW201919690A (zh) 2019-06-01
PE20201443A1 (es) 2020-12-10
US20200206331A1 (en) 2020-07-02
GEP20227386B (en) 2022-06-10
AU2018302767A1 (en) 2020-03-05
PH12020500133A1 (en) 2021-02-08
CA3070039A1 (en) 2019-01-24
KR20200042470A (ko) 2020-04-23
CN111032078A (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
UY37811A (es) Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
MX2021000193A (es) Selección de epítopos de vacunas personalizadas contra el cáncer.
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
BR112018002406A2 (pt) anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos
AR092896A1 (es) Composiciones inmunogenicas
AR041880A1 (es) Composicion inmunogena
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
BRPI0607551A2 (pt) vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso
WO2015142671A3 (en) Influenza virus vectors and uses therefor
PE20100366A1 (es) Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
PH12020550924A1 (en) Heptatitis b virus (hbv) vaccines and uses thereof
MX2022009167A (es) Formulaciones para vacuna contra coronavirus.
PE20200004A1 (es) Composicion de vacuna multivalente novedosa
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
AR088907A1 (es) Vacuna
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
BR112019010227A2 (pt) conjugado imunogênico, processo para preparação de conjugado imunogênico, composição imunogênica, vacina, e, uso de nomv
BR112017004181A2 (pt) ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1?
AR101256A1 (es) Composición vacunal que comprende ipv y ciclodextrinas
BR112023019301A2 (pt) Formulações de vacina de coronavírus
AR116631A1 (es) Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma
BR112018000037A2 (pt) partículas semelhantes a vírus recombinantes usando a proteína gag do vírus da imunodeficiência bovina (vlp de bgag), vacina, vetor plasmidial de transferência para produzir a vlp de bgag, método para fazer a vlp de bgag, método para preparar a vacina